Brokerages on Sun Pharma Q4 results: Most stay bullish but cut target price in Rs 470-540 range
Updated : May 29, 2019 08:45 AM IST
Sun Pharma reported a 53 percent drop in its net profit to Rs 635.9 crore for the quarter ended March 2019.
Citi Research placed the highest target price on Sun Pharma at Rs 540 per share, saying that the underlying numbers and trends indicate improvement QoQ.
Morgan Stanley gave a 'sell' call with a price target of Rs 470 per share.
Have you signed up for Primo, our daily newsletter?It has all the stories and data on the market, business, economy and tech that you need to know.
THANK YOU! You made our day. See you every morningYOUR EMAIL IS ON ITS WAY. Check your inbox for future updates.
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more